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Background: Cachexia is a state of involuntary weight loss common to many chronic diseases. Experimental data,
showing that cachexia is related to the enhancement of acute phase response reaction, led to the new definition
of cachexia that included, aside from the principal criterion of weight loss, other “minor criteria”, Amongst them are
levels of C-reactive protein (CRP), albumin and hemoglobin. However, there is paucity of data regarding possible
differences of these laboratory parameters in patients with various diseases known to be related to cachexia.
Methods: CRP, albumin and hemoglobin were evaluated in 119 patients, divided into two disease groups,
hematological (ones with diagnosis of non-Hodgkin lymphoma or Hodgkin disease) and non-hematological (solid
tumor patients and patients with chronic heart failure). Patients were further subdivided into two nutritional groups,
cachectic and non-cachectic ones according to the principal criterion for cacxehia i.e. loss of body weight.
Results: We found that cachectic patients had higher levels of CRP, and lower levels of both hemoglobin and
albumin compared to non-cachectic patients, regardless of the disease group they fitted. On the other hand, the
group of hematological patients had lower levels of CRP primarily due to the differences found in the
non-cachectic group. Higher levels of albumin were also found in the hematological group regardless of the
nutritional group they fitted. Limitations of cut-off values, proposed by definition, were found, mostly regarding
their relatively low sensitivity and low negative predictive value.
Conclusions: As expected, differences in values of routine laboratory parameters used in definition of cachexia
were found between cachectic and non-cachectic patients. Their values differed between hematological and
non-hematological patients both in cachectic and non-cachectic group. Cut-off levels currently used in definition of
cachexia have limitations and should be further evaluated.
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Cachexia is a state of involuntary weight loss common
to many patients with chronic diseases such as cancer,
acquired immunodeficiency syndrome, congestive heart
failure, chronic infections, rheumatoid arthritis and kid-
ney failure [1,2]. It was described centuries ago [3,4] and
it is estimated that 5 million people in United States of
America develop cachexia annually [5], with 2 million
deaths relating to it [6] together with some other adverse
prognostic features [7,8].
The mechanism of development of cachexia in all
these conditions is believed to be similar if not the
same [9]. Cachexia is believed to be a result of activa-
tion of acute phase response through upregulation of
proinflammatory cytokines [10-12]. This upregulation
is a consequence of various aforementioned diseases
[13] and additionally, in cancer patients, cachexia is
believed to be also induced by tumor products called
proteolysis-inducing and lipid-mobilizing factors [14].
Those changes lead to alterations in metabolism of
protein, fat and carbohydrates responsible for reduc-
tion in body weight as well as changes in body com-
position [15,16]. Upregulation of proinflammatory
cytokines leads to elevated levels of C- reactive pro-
tein (CRP) and albumin [17,18] and chronic inflam-
mation is also related to the development of anemia
frequently referred as anemia of the chronic disease
[19,20].
Relation between chronic inflammation, as a trigger
for development of cachexia, and the subsequent
changes in certain clinical and laboratory features
lead key opinion leaders to incorporate, beside princi-
pal criterion for the diagnosis of cachexia which is at
least 5% loss of edema – free body weight during the
previous 12 months or less, other “minor criteria”
into the new definition of cachexia. Amongst those
“minor criteria” are elevated levels of CRP (≥ 5 mg/l)
and decreased levels of hemoglobin (≤ 12 g/dl) and
albumin (≤ 3.2 g/dl) [21] which were in the focus of
our study.
Although it is well known that cachexia occurs in
different diseases, comparative clinical or laboratory
studies are lacking. Aim of the present study was to in-
vestigate whether there are differences between afore-
mentioned routine laboratory parameters between
patients with hematological diseases and other patients
with diseases known to be related to cachexia (i.e. other
solid tumors, chronic heart failure). First, we examined
those parameters in all patients included in this study,
thereafter investigating same parameters in cachectic
and non-cachectic patients. Finally, we examined the
proposed cut-off values of CRP, hemoglobin and albu-
min for diagnosis of cachexia, in order to establish their
clinical usefulness.Methods
Patients
The study was conducted at the Department of Internal
Medicine of University Hospital Merkur in Zagreb.
Patients' data were collected from May 2011 until February
2012 on consecutive patients that were eligible for
entry. A diagnosis of either solid hematological tumors
(non-Hodgkin lymphoma, Hodgkin disease), other solid
tumors of any site or chronic heart failure of any eti-
ology was mandatory. Diagnosis of malignant disease
had to be proven with adequate histopathological sam-
ple. Diagnosis of heart failure was made according to
the guidelines criteria [22].
Exclusion criteria were age of less than 18 years,
starvation, malabsorption, diarrhea, active thyroid dis-
ease, depression or other severe psychiatric disease,
chronic obstructive pulmonary disease, renal insuffi-
ciency of grade ≥ 3, myocardial infarction in less than last
12 weeks, liver insufficiency, neuromuscular diseases, al-
cohol or drug abuse and previous use of cardiotoxic
chemotherapy in doses proven to be cardiotoxic [23].
The study received previous local ethical board ap-
proval and was conducted according to the Declaration
of Helsinki and its subsequent amendments. All patients
gave written informed consent before participation in
the study.
Evaluation of patients
Complete history was recorded, full physical examina-
tions were performed and blood samples were collected
at baseline. Baseline blood analyses included complete
blood count and complete biochemistry (including
values of hemoglobin, CRP and albumin). All measure-
ments were done according to the standard protocol of
institutional laboratory.
Patients were considered to be cachectic if they fulfilled
main criteria for the diagnosis according to the consensus
document. This criterion is loss of ≥ 5% of body weight in
last 12 months or less (no less than 6 months). Other cri-
teria (decreased muscle strength, fatigue, anorexia, low fat
free index, abnormal values of CRP, hemoglobin or albu-
min), of which 3 of 5 need to be fulfilled for diagnosis,
were also sought but we did not include them in the strati-
fication of our patients [21].
Patients were further divided into two disease groups,
hematological (ones with diagnosis of non-Hodgkin lymph-
oma or Hodgkin disease) and non-hematological (solid
tumor patients and patients with chronic heart failure).
Measurements of CRP and albumin were performed on
the Beckman Coulter Olympus AU 680 analyzer (Olympus
Mishima Co., Ltd., Shizuoka, Japan) using Beckman Coulter
System reagents and standardized laboratory methods on
fresh sera on the day of blood collection. Serum was
collected after centrifugation for 15 minutes at 3000 rpm.
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sensitivity latex-enhanced immuno-turbidimetric assay.
The calibrator CRP values were traceable to CRM 470. The
limit of detection was 0.1 mg/L. Quantitative determination
of albumin in serum was performed using Beckman
Coulter bromocresol green photometric color test. Mea-
surements of hemoglobin was performed on the Sysmex
XE-2100 (Sysmex, Kobe, Japan), fully automated discrete
hematology analyzer designed to generate complete blood
counts. Hemoglobin determination was achieved using
the sodium laurel sulfate (SLS)-hemoglobin method. Par-
ticipation of Institute of Clinical Chemistry and Labora-
tory Medicine University Hospital Merkur accredited
according to ISO 15189 (1,2) in the International External
Quality Assessment Schemes for general and special med-
ical biochemistry organized by World Health Organization
for Laboratory Hematology (IEQAS - H) and by LABQU-
ALITY, Finland for biochemical tests, confirms clinical re-
liability of obtained laboratory test results [24].
Statistics
The results were expressed as the mean +/− standard
deviation or as a proportion of the total number. Ana-
lyses of specificity, sensitivity, positive predictive value
and negative predictive value were done using appropri-
ate formulas. Differences in proportions (categorical
variables) were compared using chi square test. Mann
Whitney test was used to test the equality of continuous
variables. A p-value < 0.05 was considered statistically
significant. All statistics were performed with the Stat-




One hundred nineteen (76 males; median age 62 years)
consecutive patients were enrolled. Fifty five patients were
from the hematological group (45 had diagnosis of non-
Hodgkin lymphoma and 10 had diagnosis of Hodgkin
disease). In the non-hematological group 43 patients
were diagnosed with solid tumor of various sites (19
hepatocellular cancer, 8 colorectal cancer, 8 pancreatic
cancer, 3 billiary duct cancer, 2 gastric cancer, 3 cancerTable 1 Clinical characteristics of patients
Characteristic
Number
Age years (mean; SD)
Men
Cachectic (n/%)
Lost body weight in kg in cachectic patients (mean; SD)
Period of body weight loss in cachectic patients in months (mean; SD)
Abbreviations: n = number, SD = standard deviation, kg = kilograms.of unknown primary site) and 21 had chronic heart fail-
ure (15 had ischemic cardiomyopathy and 6 had non-
ischemic cardiomyopathy). In the group of heart failure
patients 2 (10%) were in NYHA class I, 8 (38%) patients
were in stage II, 9 (42%) were in stage III, and the
remaining 2 (10%) in stage IV.
Hematological patients were significantly younger than
non hematological patients. We found no statistically
significant differences in prevalence of cachexia, lost
body weight in cachectic patients or period of loss of
body weight in cachectic patients between prespecified
disease groups. Patient clinical characteristics are shown
in Table 1.
Differences in values of CRP, hemoglobin and albumin
between groups
Mean value of CRP in the whole group was 22.78 mg/l
(+/−37.5). Hematological patients had mean value of
CRP 15.98 mg/l (+/−36.1) and non-hematological patients
had a mean value of CRP 28.71 mg/l (+/−39.1). Observed
difference was found to be statistically significant
(p = 0.048). When we subdivided patients according to
their nutritional status, cachectic patients as a whole
group had a mean CRP value of 34.18 mg/l (+/−51.9) and
patients without cachexia had a mean value of CRP 17.57
mg/l (+/−27.5) which was also significantly different
(p = 0.021). On the other hand, we could not find signifi-
cant differences in CRP levels in hematological (32.90 mg/
l (+/−64.5) vs. 9.75 mg/l (+/−12.9); p = 0.1) or in non-
hematological (35.26 mg/l (+/−43.0) vs. 25.55 mg/l
(+/−35.6); p=0.27) group when we divided them according
to their cachectic status. In fact the observed initial differ-
ence was related to the difference between hematological
and non-hematological patients in the non-cachectic
group (9.75 mg/l (+/−12.9) vs. 25.55 mg/l (+/−35.6);
p = 0.01). CRP levels according to the predefined groups
are shown in Table 2.
Mean value of hemoglobin in all examined patients
was 12.53 g/dl (+/−2.1). Cachectic patients had lower
levels of hemoglobin (11.73 g/dl (+/−2.0) vs. 12.90 g/dl
(7.9-16.2); p = 0.039) than non-cachectic patients. There
was no difference in values of hemoglobin between
hematological and non-hematological patients (12.70 g/dlHematological Non-hematological p-value
55 64
56.85 (+/−14.58) 67.75 (+/−13.03) p < 0.0001*
37 (67%) 39 (61%) NS
15/27 27/35 NS
10.15 (+/−6.39) 11.51 (+/−7.25) NS
11.69 (+/−10.69) 14.53 (+/−17.93) NS
Table 2 Values of CRP levels according to predefined groups
All Cachectic Non-cachectic p-value (C vs. NC)
All 22.78 (+/−37.5) 34.18 (+/−51.9) 17.57 (+/−27.5) p = 0.021*
Hematological 15.98 (+/−36.1) 32.90 (+/−64.5) 9.75 (+/−12.9) p = 0.1
Non-hematological 28.71 (+/−39.1) 35.26 (+/−43.0) 25.55 (+/−35.6) p = 0.27
p-value (H vs. NH) p = 0.048* p = 0.43 p = 0.01*
Abbreviations H = hematological, NH = non-hematological, C = cachectic, NC = non-cachectic. Values of CRP levels are in mg/l. *statistically significant.
(mean +/− standard deviation).
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lyzes done in the same way as for CRP values showed only
statistically significant difference in hematological group
depending on their nutritional status (11.20 g/dl (+/−2.2)
vs. 13.27 g/dl (+/−2.0); p = 0.003). Hemoglobin levels
according to the groups are shown in Table 3.
Mean level of albumin for all patients was 38.3 g/l
(+/−6.5). Cachectic patients had lower levels of albumin
(34.95 g/l (+/− 6.5) vs. 39.85 g/l (+/−5.8); p = 0.0002)
both as a group and when divided into hematological
(38.05 g/l (+/−6.1) vs. 42.04 g/l (+/−5.2); p = 0.019) and
non-hematological ones (32.83 g/l (+/−6.1) vs. 37.85 g/l
(+/−5.7); p = 0.004). On the other hand, hematological
patients had higher level of albumin than non-
hematological patients (40.95 g/l (+/−6.1) vs. 36.01
(+/−6.2); p = 0.0001) regardless of their nutritional sta-
tus. Values of albumin levels are shown in Table 4.
Evaluation of proposed cut-offs
Finally, we analyzed values of proposed cut-offs for
CRP (≥ 5 mg/l), hemoglobin (≤ 12.0 g/dl) and albumin
(≤ 32.0 g/l) both separately and together in the whole group
of patients and upon dividing them into hematological and
non-hematological groups. Sensitivities for the whole group
were found to be 76% for CRP, 59% for hemoglobin, 35%
for albumin and 86% for either of them being positive.
Specificity was 39% for CRP, 68% for hemoglobin, 85% for
albumin and 29% for either of them being positive.
Negative predictive values were 78% for CRP, 79% for
hemoglobin, 74% for albumin and 83% for all of them being
negative. On the other hand, positive predictive value for
CRP cut-off was 36%, for hemoglobin 46%, for albumin
52% and for either of them being positive 35%.
In hematological group, sensitivity of CRP was 73%,
specificity 50%, negative predictive value was 83% and
positive predictive value 35%. For hemoglobin, valuesTable 3 Values of hemoglobin levels according to predefined
All Cachecti
All 12.53 (+/−2.1) 11.73 (+/
Hematological 12.70 (+/−2.3) 11.20 (+/
Non-hematological 12.38 (+/−1.9) 12.09 (+/
p-value (H vs. NH) p = 0.33 p = 0.16
Abbreviations H = hematological, NH = non-hematological, C = cachectic, NC = non
(mean +/− standard deviation).were 73%, 75%, 88% and 52% and for albumin they were
25%, 92%, 75% and 50%, respectively. For all three values
being either above or below proposed cut-offs values
were 87%, 37%, 88%, 65%. Similar data were observed in
non-hematological group and were for CRP for sensitiv-
ity 77%, 29% for specificity, 70% for negative predictive
value and 36% for positive predictive value. For
hemoglobin values were 50%, 62%, 70% and 40% and for
albumin they were 45%, 79%, 73% and 53%. For all three
cut-offs we got 92% sensitivity, 21% specificity, 75%
negative predictive value and 45% of positive predictive
value. Data for CRP, hemoglobin and albumin are shown
in Figures 1, 2, 3.
Proposed cut-off for CRP did not significantly differenti-
ate cachectic and non-cachectic patients neither in a
whole group (p = 0.12) nor in hematological (p = 0.12) or
non-hematological (p = 0.61) patients separately. Hemog-
lobin cut-off was able to discriminate cachectic and
non-cachectic patients in the whole group (p = 0.043) and
in hematological patients (p = 0.01) but not in non-
hematological group of patients (p = 0.36). On the other
hand, albumin cut-off discriminated well between cach-
ectic and non-cachectic patients both in all patients
(p = 0.011) and in non-hematological patients (p = 0.04),
but not in hematological patients (p = 0.18). All three
values being above or below the proposed cut-offs could
not discriminate between cachectic and non-cachectic
patients observed either together (p = 0.06) or separately as
hematological (p = 0.08) or non-hematological (p = 0.44).
Discussion
Before discussing further our results we believe that
three possible questions, that may arise reading this
paper, need to be clarified. Firstly, the rational to divide
our patients into hematological and non-hematological
group. Would it not have been more appropriate togroups
c Non-cachectic p-value (C vs. NC)
−2.0) 12.90 (+/−2.0) p = 0.039*
−2.2) 13.27 (+/−2.0) p = 0.003*
−1.8) 12.53 (+/−2.0) p = 0.27
p = 0.07
-cachectic. Values of hemoglobin levels are in g/dl. *statistically significant.
Table 4 Values of albumin levels according to predefined groups
All Cachectic Non-cachectic p-value (C vs. NC)
All 38.31 (+/−6.5) 34.95 (+/−6.5) 39.85 (+/−5.8) p = 0.0002*
Hematological 40.95 (+/−6.1) 38.05 (+/−6.1) 42.04 (+/−5.2) p = 0.019*
Non-hematological 36.01 (+/−6.2) 32.83 (+/−6.1) 37.85 (+/−5.7) p = 0.004*
p-value (H vs. NH) p = 0.0001* p = 0.02* p = 0.0001*
Abbreviations H = hematological, NH = non-hematological, C = cachectic, NC = non-cachectic. Values of albumin levels are in g/l. *statistically significant.
(mean +/− standard deviation).
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and solid tumors) and those with chronic benign state
(chronic heart failure)? Would it not have been more
appropriate to compare patients in the three separate
groups i.e. hematological, solid tumors and heart failure
group? There are several explanations for our decision.
Our institution is a referral center for hematological dis-
eases and most of the patients admitted to our institution
indeed suffer from hematological diseases. Fewer patients
are admitted for solid tumors, heart failure and other
diseases related to cachexia. By dividing our patients in
hematological and non-hematological ones we have
achieved optimal balance of consecutive patients in re-
spective groups. However, the answer is not just of
technical or statistical matter. If one would be really inter-
ested, and it was indeed our intention, to investigate dif-
ferences between hematological and patients with other
diseases related to cachexia how is one supposed to divide
patients? Dividing patients into three groups, apart from
creating numerically unbalanced groups would not answer
this question. In fact, in order to get the correct answer to
this question a comparison between hematological patients
and all other groups of patients with diseases that can
cause cachexia would be necessary. Unfortunately, such a
study could not have been conducted in our institution al-
though we eagerly await a study by others that would ad-
dress this question.
Secondly, we decided to divide patients into cachectic
and non-cachectic just according to the main criterion
that is loss of at least 5% of body weight during the pre-








Figure 1 Value of proposed cut-off for CRP (%). Abbreviations: NPV = n
H = hematological, NH = non-hematological.criteria proposed by new definition that we refer to [21].
We think that such, at first glance, arbitrary division is
founded on the majority of the existing experimental
data that defined cachexia just as s state with a certain
amount of weight loss during variable time frame. Al-
though we do not question the new definition we still
think it can be subjected to various tests. One of them
could be determining relations between its major and
minor criteria. Comparing results of minor criteria upon
establishing groups of patients after using major criteria
is just that. In accordance with our work also goes the
new proposed definition for cancer cachexia which states
that only the loss of weight of 5% for 6 months is a cri-
terion enough to diagnose cancer cachexia [25].
And lastly we decided, as is obvious from our patient
characteristics, to enroll patients that had weight loss for
more than 12 months. We think that it is justifiable, al-
though the definition that we refer to [21] states the
weight loss should be in 12 months or less. But the
authors also state that “. . . .time frame may be disease
specific and is likely to be shorter in cancer (3–6 months)
and longer in chronic heart failure and kidney disease
(12 months). . . . .”. Although this sentence may imply the
upper limit of 12 months we believe that it also may
imply periods longer than 12 months. Some of the pub-
lished data refers to periods exceeding 12 months, as
was the case in one of the pivotal studies from Anker
et al. with duration of weight loss at inclusion up to 13
months. After inclusion patients were followed for a
mean of 686 days which is almost two years [26]. In that















Figure 2 Value of proposed cut-off for hemoglobin (%). Abbreviations: NPV = negative predictive value, PPV = positive predictive value,
H = hematological, NH = non-hematological.
Letilovic et al. Nutrition Journal 2013, 12:6 Page 6 of 8
http://www.nutritionj.com/content/12/1/6loss after inclusion were not excluded from follow up
and we have followed the same reasoning in our investi-
gation. It is especially important in patients with durable
survival in spite of their disease (hematological patients
with lymphomas, some cancer patients, heart failure
patients) so periods of loss of body weight can be longer.
Given the scarcity of data regarding clinical and la-
boratory features comparing patients with various dis-
eases that are related to cachexia we conducted our
study to address some of these issues. We were specific-
ally focused on differences between hematological and
non-hematological patients. We found, as others did,
that cachectic patients as a group, had significantly
higher levels of CRP and lower levels of both albumin
and hemoglobin. Secondly, we divided patients into
hematological and non-hematological groups and found
that hematological patients had significantly lower levels
of CRP and higher levels of albumin. There was no dif-
ference in levels of hemoglobin. When we further subdi-
vided patients into cachectic and non-cachectic groups
we found that the differences observed for CRP were
mainly due to differences found in non-cachectic group.
Observed differences in albumin levels were present regard-
less of this subdivision. Hematological cachectic patients
had lower levels of hemoglobin than non-cachectic ones.
The same was not true for non-hematological patients.








Figure 3 Value of proposed cut-off for albumin (%). Abbreviations: NPV
H = hematological, NH = non-hematological.pathophysiology between the groups of patients as we
divided them. Unfortunately, we were not able to conduct
investigations regarding possible differences in for example
expression of inflammatory cytokines that could explain
observed differences. Because of that our question “is there
only one cachexia?”, although provocative, remains purely
speculative and awaits further trials with larger numbers of
patients and more balanced groups exploring other features
of cachexia, probably primarily those incorporated into pro-
posed definition [21]. New proposed definition orientating
just on cancer cachexia is in the line with our work i.e. it
already recognizes the existence of “different” types of
cachexia [25].
We then evaluated proposed cut-offs for CRP (≥ 5mg/L),
hemoglobin (≤ 12 g/dl) and albumin (≤ 3.2 g/dl) and
found that CRP had highest sensitivity, followed by
hemoglobin and albumin. Inverse relationship was found
for specificity. Cut-offs were found to have relatively good
negative predictive value whereas positive predictive value
was poor. Combining all three cut-offs just emphasized
above mentioned relations. When we divided patients to
the hematological and non-hematological groups, pro-
posed cut-offs followed same trends as in the whole group.
Proposed cut-off for CRP was not able to distinct cachec-
tic from non-cachectic patients in the whole group nor
was it able to distinct them when we further subdivided




= negative predictive value, PPV = positive predictive value,
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to distinct patients according to their nutritional status
regardless of further subdivisions. Hemoglobin cut-off
showed its predictive power in both whole group as well
as in hematological group but not in non-hematological
group. Although such results would imply that CRP
cut-off is least effective and albumin cut-off is the most ef-
fective one such conclusions would need larger studies
powered enough even to give more precise values. Until
then, our results serve as ones that arouse suspicion in
proposed cut-offs.
Conclusions
Patients suffering from diseases related to cachexia have
elevated values of routine laboratory parameters related
to enhanced inflammation. We found significant differ-
ences between these values for cachectic and non-
cachectic groups of patients. We also revealed some sig-
nificant differences between these values when dividing
patients into hematological or non-hematological groups,
although we are well aware of the relatively small number
of patients in groups and of the variability of patients’
diagnoses especially in the group of patients with solid
tumors. We are also aware of the difference in age be-
tween the hematological and non-hematological group
that could have influenced our results. These restrictions
stopped us from attributing observed differences to differ-
ences in pathophysiological mechanisms of exaggerated
immune response in different diseases. On the other hand,
limitations of our study certainly cannot allow anyone to
conclude that those differences in fact actually do not
exist. To our knowledge, this is the first study that tries to
compare between groups of patients suffering from the
different diseases that can cause cachexia. Further studies
with larger numbers of patients and with smaller variabil-
ity inside the groups are warranted for further clarification
of possible differences between the cachexia presenting in
various diseases.
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